Clinical Trial Update: A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. [Phase 2]

View source ↗

Summary

A Phase II clinical trial update indicates the combination of AK104 and AK112 with TT-00420 tablet for advanced hepatocellular carcinoma is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• AK112
• TT-00420 tablet (TT-00420)

Snippet

Sponsor: Akeso | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING